Catalyst Pharmaceuticals Announces Abstract on Lambert Eaton

CORAL GABLES, Fla., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for

Related Keywords

Singapore , Canada , United States , American , America , Patrickj Mcenany , David Morrell , David Schull Russo , Lambert Eaton , Catalyst Pharmaceuticals Inc , Health Canada , American Cancer Society , Global Health , Marketing At Catalyst Pharmaceuticals , Exchange Commission , Health Services , Investor Contact Mary Coleman Catalyst Pharmaceuticals Inc , Health Economics , Lung Cancer , International Association , Real World , Lambert Eaton Myasthenic Syndrome , Small Cell Lung Cancer , North America , Duchenne Muscular , Fast Track , Catalyst Pharmaceuticals , Full Prescribing , Safety Information , Full Prescribing Information , Key Statistics , Rev Dis Primers , Clin Oncol , Thorac Oncol , Annual Report , Contact Mary Coleman Catalyst Pharmaceuticals , Contact David Schull Russo Partners , Glems , Small Cell , Ncology , Irdapse , Epilepsy , Rare Disease , Neuromuscular , Eurology , Muscle Weakness , Myasthenia , Autoimmune , Dancer , Young , Prescription Drugs , Medical Research , Medication , Health ,